MX2015008829A - Momelotinib deuterado. - Google Patents

Momelotinib deuterado.

Info

Publication number
MX2015008829A
MX2015008829A MX2015008829A MX2015008829A MX2015008829A MX 2015008829 A MX2015008829 A MX 2015008829A MX 2015008829 A MX2015008829 A MX 2015008829A MX 2015008829 A MX2015008829 A MX 2015008829A MX 2015008829 A MX2015008829 A MX 2015008829A
Authority
MX
Mexico
Prior art keywords
momelotinib
deuterated
formula
compound
pharmaceutically acceptable
Prior art date
Application number
MX2015008829A
Other languages
English (en)
Inventor
Robert Silverman
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2015008829A publication Critical patent/MX2015008829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La presente invención se refiere a un compuesto de Fórmula I, o una sal del mismo farmacéuticamente aceptable, en donde las variables mostradas en la Fórmula I son como se definen en la especificación.
MX2015008829A 2013-01-09 2014-01-08 Momelotinib deuterado. MX2015008829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750802P 2013-01-09 2013-01-09
PCT/US2014/010760 WO2014110189A1 (en) 2013-01-09 2014-01-08 Deuterated momelotinib

Publications (1)

Publication Number Publication Date
MX2015008829A true MX2015008829A (es) 2016-04-25

Family

ID=51167356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008829A MX2015008829A (es) 2013-01-09 2014-01-08 Momelotinib deuterado.

Country Status (8)

Country Link
US (2) US9518027B2 (es)
EP (1) EP2943489B1 (es)
JP (1) JP2016505015A (es)
AU (1) AU2014205472B2 (es)
CA (1) CA2897814C (es)
ES (1) ES2672468T3 (es)
MX (1) MX2015008829A (es)
WO (1) WO2014110189A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014205472B2 (en) 2013-01-09 2018-05-10 Concert Pharmaceuticals Inc. Deuterated momelotinib
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
EP3713660A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
US20200281857A1 (en) 2017-11-22 2020-09-10 Dauntless 1, Inc. Therapeutic compound formulations
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
BRPI0808888B8 (pt) 2007-03-12 2021-05-25 Cytopia Res Pty Ltd composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
JP2012531433A (ja) 2009-06-25 2012-12-10 メドリューション リミテッド キナーゼ阻害剤としての置換複素環式化合物とその用法
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AU2014205472B2 (en) 2013-01-09 2018-05-10 Concert Pharmaceuticals Inc. Deuterated momelotinib
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物

Also Published As

Publication number Publication date
AU2014205472B2 (en) 2018-05-10
CA2897814A1 (en) 2014-07-17
AU2014205472A1 (en) 2015-07-23
US9776973B2 (en) 2017-10-03
WO2014110189A1 (en) 2014-07-17
US9518027B2 (en) 2016-12-13
EP2943489B1 (en) 2018-04-11
ES2672468T3 (es) 2018-06-14
CA2897814C (en) 2022-06-21
JP2016505015A (ja) 2016-02-18
EP2943489A4 (en) 2016-06-08
EP2943489A1 (en) 2015-11-18
US20150361051A1 (en) 2015-12-17
US20170144977A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
MX2015002040A (es) Baricitinib deuterado.
IN2015DN00598A (es)
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MA39749A (fr) Dérivés de pipéridine-dione
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MX2015008829A (es) Momelotinib deuterado.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
PH12018500903A1 (en) Pyranodipyridine compound
IN2014DN07996A (es)
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
MX2016016127A (es) Formas cristalinas.
MX2015012610A (es) Pacritinib deuterizado.
EA201690593A1 (ru) Новые соединения мочевины
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями
UA89447U (ru) Соединение 1,1-диэтилкарбокси-2-хлор-2-трифторметилэтилен с потенциальными физиологическими свойствами
UA87254U (ru) Соединение 1,1-диэтилкарбокси-2-метокси-2-трифторметилэтилен с потенциальными физиологическими свойствами